Advertisement

Diagnostic Approaches to Hematopoietic Disorders of the Spleen and Liver

  • Ling ZhangEmail author
  • Pukhraz Basra
  • Serhan Alkan
Chapter
  • 138 Downloads

Abstract

The spleen is the largest lymphoid tissue in the human body and is composed of red and white pulp along with the supporting stroma. It is an important organ for filtration, immune regulation, and hematopoiesis during fetal development. Although the intact immune modulation from the spleen would protect human beings from diseases, there are a number of primary and secondary hematologic malignancies that may occur when immunity of the spleen is compromised or overridden by other processes. Additional non-hematopoietic diseases affecting the spleen include, but are not limited to, viral, bacterial, fungal, and parasitic infections, sarcoidosis, and storage disorders; these diseases may sometimes mimic primary hematologic neoplasms. The chapter will focus on conventional diagnostic approaches to hematologic disorders of the liver and spleen, mainly including gross and microscopic examination and immunophenotyping. Biopsy indications and histology processes have also been discussed.   

Keywords

Splenectomy Liver biopsy Grossing Microscopic examination Ancillary tests Special staining Flow cytometry Immunohistochemical staining 

References

  1. 1.
    Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005;5(8):606–16.PubMedGoogle Scholar
  2. 2.
    Bronte V, Pittet MJ. The spleen in local and systemic regulation of immunity. Immunity. 2013;39(5):806–18.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Corless JK, Middleton HM 3rd. Normal liver function. A basis for understanding hepatic disease. Arch Intern Med. 1983;143(12):2291–4.PubMedGoogle Scholar
  4. 4.
    Torbenson M, Zen Y, Yeh M. Tumors of the liver. Washington, D.C.: ARP Press; 2018.Google Scholar
  5. 5.
    Hiatt J, Phillips E, Morgenstern L. Surgical diseases of the spleen. Heidelberg: Springer; 1997.Google Scholar
  6. 6.
    Johnson HA, Deterling RA. Massive splenomegaly. Surg Gynecol Obstet. 1989;168(2):131–7.PubMedGoogle Scholar
  7. 7.
    Lehne G, Hannisdal E, Langholm R, Nome O. A 10-year experience with splenectomy in patients with malignant non-Hodgkin’s lymphoma at the Norwegian Radium Hospital. Cancer. 1994;74(3):933–9.PubMedGoogle Scholar
  8. 8.
    Lv Y, Lau WY, Li Y, et al. Hypersplenism: history and current status. Exp Ther Med. 2016;12(4):2377–82.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Cadili A, de Gara C. Complications of splenectomy. Am J Med. 2008;121(5):371–5.PubMedGoogle Scholar
  10. 10.
    Machado NO, Grant CS, Alkindi S, et al. Splenectomy for haematological disorders: a single center study in 150 patients from Oman. Int J Surg. 2009;7(5):476–81.PubMedGoogle Scholar
  11. 11.
    Dendle C, Sundararajan V, Spelman T, Jolley D, Woolley I. Splenectomy sequelae: an analysis of infectious outcomes among adults in Victoria. Med J Aust. 2012;196(9):582–6.PubMedGoogle Scholar
  12. 12.
    Alzen G, Basedow J, Luedemann M, Berthold LD, Zimmer KP. Partial splenic embolization as an alternative to splenectomy in hypersplenism–single center experience in 16 years. Klin Padiatr. 2010;222(6):368–73.PubMedGoogle Scholar
  13. 13.
    Amin MA, el-Gendy MM, Dawoud IE, Shoma A, Negm AM, Amer TA. Partial splenic embolization versus splenectomy for the management of hypersplenism in cirrhotic patients. World J Surg. 2009;33(8):1702–10.PubMedGoogle Scholar
  14. 14.
    George JN, Woolf SH, Raskob GE, et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood. 1996;88(1):3–40.PubMedGoogle Scholar
  15. 15.
    Kappers-Klunne MC, Wijermans P, Fijnheer R, et al. Splenectomy for the treatment of thrombotic thrombocytopenic purpura. Br J Haematol. 2005;130(5):768–76.PubMedGoogle Scholar
  16. 16.
    Bonnet S, Guedon A, Ribeil JA, Suarez F, Tamburini J, Gaujoux S. Indications and outcome of splenectomy in hematologic disease. J Visc Surg. 2017;154(6):421–9.PubMedGoogle Scholar
  17. 17.
    Katz SC, Pachter HL. Indications for splenectomy. Am Surg. 2006;72(7):565–80.PubMedGoogle Scholar
  18. 18.
    Singh AK, Shankar S, Gervais DA, Hahn PF, Mueller PR. Image-guided percutaneous splenic interventions. Radiographics. 2012;32(2):523–34.PubMedGoogle Scholar
  19. 19.
    Patel N, Dawe G, Tung K. Ultrasound-guided percutaneous splenic biopsy using an 18-G core biopsy needle: our experience with 52 cases. Br J Radiol. 2015;88(1055):20150400.PubMedPubMedCentralGoogle Scholar
  20. 20.
  21. 21.
    Abbott RM, Levy AD, Aguilera NS, Gorospe L, Thompson WM. From the archives of the AFIP: primary vascular neoplasms of the spleen: radiologic-pathologic correlation. Radiographics. 2004;24(4):1137–63.PubMedGoogle Scholar
  22. 22.
    O’Malley DP, George T, Orazi A, Abbondanzo S. Benign and reactive conditions of lymph node and spleen, vol. 7. Washington, D.C.: American Registery of Pathology; 2009.Google Scholar
  23. 23.
    Lester. Manual of surgical pathology. Philadelphia: Churchill Livingstone; 2001.Google Scholar
  24. 24.
    Wotherspoon A, Attygalle A, Mendes LS. Bone marrow and splenic histology in hairy cell leukaemia. Best Pract Res Clin Haematol. 2015;28(4):200–7.PubMedGoogle Scholar
  25. 25.
    Urrutia M, Mergo PJ, Ros LH, Torres GM, Ros PR. Cystic masses of the spleen: radiologic-pathologic correlation. Radiographics. 1996;16(1):107–29.PubMedGoogle Scholar
  26. 26.
    Morgenstern L. Nonparasitic splenic cysts: pathogenesis, classification, and treatment. J Am Coll Surg. 2002;194(3):306–14.PubMedGoogle Scholar
  27. 27.
    McInnes MD, Kielar AZ, Macdonald DB. Percutaneous image-guided biopsy of the spleen: systematic review and meta-analysis of the complication rate and diagnostic accuracy. Radiology. 2011;260(3):699–708.PubMedGoogle Scholar
  28. 28.
    Keogan MT, Freed KS, Paulson EK, Nelson RC, Dodd LG. Imaging-guided percutaneous biopsy of focal splenic lesions: update on safety and effectiveness. AJR Am J Roentgenol. 1999;172(4):933–7.PubMedGoogle Scholar
  29. 29.
    Civardi G, Vallisa D, Berte R, et al. Ultrasound-guided fine needle biopsy of the spleen: high clinical efficacy and low risk in a multicenter Italian study. Am J Hematol. 2001;67(2):93–9.PubMedGoogle Scholar
  30. 30.
    Tam A, Krishnamurthy S, Pillsbury EP, et al. Percutaneous image-guided splenic biopsy in the oncology patient: an audit of 156 consecutive cases. J Vasc Interv Radiol. 2008;19(1):80–7.PubMedGoogle Scholar
  31. 31.
    Friedlander MA, Wei XJ, Iyengar P, Moreira AL. Diagnostic pitfalls in fine needle aspiration biopsy of the spleen. Diagn Cytopathol. 2008;36(2):69–75.PubMedGoogle Scholar
  32. 32.
    Ramdall RB, Cai G, Alasio TM, Levine P. Fine-needle aspiration biopsy for the primary diagnosis of lymphoproliferative disorders involving the spleen: one institution’s experience and review of the literature. Diagn Cytopathol. 2006;34(12):812–7.PubMedGoogle Scholar
  33. 33.
    Gomez-Rubio M, Lopez-Cano A, Rendon P, et al. Safety and diagnostic accuracy of percutaneous ultrasound-guided biopsy of the spleen: a multicenter study. J Clin Ultrasound. 2009;37(8):445–50.PubMedGoogle Scholar
  34. 34.
    Phillips EH, Carroll BJ, Fallas MJ. Laparoscopic splenectomy. Surg Endosc. 1994;8(8):931–3.PubMedGoogle Scholar
  35. 35.
    Poulin EC, Thibault C, Mamazza J. Laparoscopic splenectomy. Surg Endosc. 1995;9(2):172–6; discussion 176–7PubMedGoogle Scholar
  36. 36.
    Bonds LA, Barnes P, Foucar K, Sever CE. Acetic acid-zinc-formalin: a safe alternative to B-5 fixative. Am J Clin Pathol. 2005;124(2):205–11.PubMedGoogle Scholar
  37. 37.
    Medeiros L, O’Malley DP, Caraway N, Vega F, Elenitoba-Johnson K, Lim M. Tumors of the lymph nodes and spleen. Washington, D.C.: ARP Press. 2017Google Scholar
  38. 38.
    Neiman RS. Incidence and importance of splenic sarcoid-like granulomas. Arch Pathol Lab Med. 1977;101(10):518–21.PubMedGoogle Scholar
  39. 39.
    Rosso R, Neiman RS, Paulli M, et al. Splenic marginal zone cell lymphoma: report of an indolent variant without massive splenomegaly presumably representing an early phase of the disease. Hum Pathol. 1995;26(1):39–46.PubMedGoogle Scholar
  40. 40.
    Borch WR, Aguilera NS, Brissette MD, O'Malley DP, Auerbach A. Practical applications in immunohistochemistry: an immunophenotypic approach to the spleen. Arch Pathol Lab Med. 2019;143(9):1093–105.PubMedGoogle Scholar
  41. 41.
    Grimm K, Barry T, Omarrley D, Weiss L. Immunophenotypic markers useful in the diagnosis and classification of hematopoietic and lymphoid neoplasms. In: Knowles’ neoplasmitc hematopathology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 1992. p. 91–118.Google Scholar
  42. 42.
    Sherman MJ, Hanson CA, Hoyer JD. An assessment of the usefulness of immunohistochemical stains in the diagnosis of hairy cell leukemia. Am J Clin Pathol. 2011;136(3):390–9.PubMedGoogle Scholar
  43. 43.
    Neiman R, Orazi A. Hematopmathologic manifestation of lymphoproliferative and myeloproliferative disorders involving the spleen. In: DM K, editor. Neoplastic hematopathology. Baltimore: Lipplincott Williams & Wilkins; 2000.Google Scholar
  44. 44.
    Du J, Shen Q, Yin H, Zhou X, Wu B. Littoral cell angioma of the spleen: report of three cases and literature review. Int J Clin Exp Pathol. 2015;8(7):8516–20.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Peckova K, Michal M, Hadravsky L, et al. Littoral cell angioma of the spleen: a study of 25 cases with confirmation of frequent association with visceral malignancies. Histopathology. 2016;69(5):762–74.PubMedGoogle Scholar
  46. 46.
    Ujjani C, Cheson BD. The current status and future impact of targeted therapies in non-Hodgkin lymphoma. Expert Rev Hematol. 2013;6(2):191–202; quiz 203PubMedGoogle Scholar
  47. 47.
    Miliotou AN, Papadopoulou LC. CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol. 2018;19(1):5–18.PubMedGoogle Scholar
  48. 48.
    Werner M, Chott A, Fabiano A, Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24(7):1016–9.PubMedGoogle Scholar
  49. 49.
    Sharpe RW, Bethel KJ. Hairy cell leukemia: diagnostic pathology. Hematol Oncol Clin North Am. 2006;20(5):1023–49.PubMedGoogle Scholar
  50. 50.
    Foucar K, Catovsky D, et al. Hairy cell leukemia. In: Swedlow S, Harris N, et al., editors. WHO classification of tumors of haematopoietic and lymphoid tissue. Lyon: LARC; 2008. p. 188–90.Google Scholar
  51. 51.
    Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med. 2011;364(24):2305–15.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Arcaini L, Zibellini S, Boveri E, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119(1):188–91.PubMedGoogle Scholar
  53. 53.
    Xi L, Arons E, Navarro W, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood. 2012;119(14):3330–2.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Thieblemont C, Davi F, Noguera ME, et al. Splenic marginal zone lymphoma: current knowledge and future directions. Oncology (Williston Park). 2012;26(2):194–202.Google Scholar
  55. 55.
    Matutes E, Morilla R, Owusu-Ankomah K, Houliham A, Meeus P, Catovsky D. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994;14(Suppl 1):57–61.PubMedGoogle Scholar
  56. 56.
    Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D, British Committee for Standards in H. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant∗. Br J Haematol. 2012;156(2):186–95.PubMedGoogle Scholar
  57. 57.
    Mason EF, Brown RD, Szeto DP, et al. Detection of activating MAP 2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. Leuk Lymphoma. 2017;58(1):233–6.PubMedGoogle Scholar
  58. 58.
    Waterfall JJ, Arons E, Walker RL, et al. High prevalence of MAP 2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46(1):8–10.PubMedGoogle Scholar
  59. 59.
    Traverse-Glehen A, Baseggio L, Bauchu EC, et al. Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity? Blood. 2008;111(4):2253–60.PubMedGoogle Scholar
  60. 60.
    Mendes LS, Attygalle A, Matutes E, Wotherspoon A. Annexin A1 expression in a splenic diffuse red pulp small B-cell lymphoma: report of the first case. Histopathology. 2013;63(4):590–3.PubMedGoogle Scholar
  61. 61.
    Curiel-Olmo S, Mondejar R, Almaraz C, et al. Splenic diffuse red pulp small B-cell lymphoma displays increased expression of cyclin D3 and recurrent CCND3 mutations. Blood. 2017;129(8):1042–5.PubMedGoogle Scholar
  62. 62.
    Colovai AI, Giatzikis C, Ho EK, et al. Flow cytometric analysis of normal and reactive spleen. Mod Pathol. 2004;17(8):918–27.PubMedGoogle Scholar
  63. 63.
    Imashuku S, Obayashi M, Hosoi G, et al. Splenectomy in haemophagocytic lymphohistiocytosis: report of histopathological changes with CD19+ B-cell depletion and therapeutic results. Br J Haematol. 2000;108(3):505–10.PubMedGoogle Scholar
  64. 64.
    Lucio P, Parreira A, van den Beemd MW, et al. Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL. Leukemia. 1999;13(3):419–27.PubMedGoogle Scholar
  65. 65.
    Zeppa P, Anniciello A, Vetrani A, Palombini L. Fine needle aspiration biopsy of hepatic focal fatty change. A report of two cases. Acta Cytol. 2002;46(3):567–70.PubMedGoogle Scholar
  66. 66.
    Howlett DC, Drinkwater KJ, Lawrence D, Barter S, Nicholson T. Findings of the UK national audit evaluating image-guided or image-assisted liver biopsy. Part I. Procedural aspects, diagnostic adequacy, and accuracy. Radiology. 2012;265(3):819–31.PubMedGoogle Scholar
  67. 67.
    Laribi K, Lemaire P, Sandrini J, Baugier de Materre A. Advances in the understanding and management of T-cell prolymphocytic leukemia. Oncotarget. 2017;8(61):104664–86.PubMedPubMedCentralGoogle Scholar
  68. 68.
    Tannapfel A, Dienes HP, Lohse AW. The indications for liver biopsy. Dtsch Arztebl Int. 2012;109(27–28):477–83.PubMedPubMedCentralGoogle Scholar
  69. 69.
    Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut. 1999;45 Suppl 4:IV1–IV11.Google Scholar
  70. 70.
    Mastoraki A, Stefanou MI, Chatzoglou E, et al. Primary hepatic lymphoma: dilemmas in diagnostic approach and therapeutic management. Indian J Hematol Blood Transfus. 2014;30(3):150–4.PubMedGoogle Scholar
  71. 71.
    Elsayes KM, Menias CO, Willatt JM, Pandya A, Wiggins M, Platt J. Primary hepatic lymphoma: imaging findings. J Med Imaging Radiat Oncol. 2009;53(4):373–9.PubMedGoogle Scholar
  72. 72.
    Gota VS, Purandare NC, Gujral S, Shah S, Nair R, Rangarajan V. Positron emission tomography / computerized tomography evaluation of primary Hodgkin’s disease of liver. Indian J Cancer. 2009;46(3):237–9.PubMedGoogle Scholar
  73. 73.
    El-Sharkawi D, Ramsay A, Cwynarski K, et al. Clinico-pathologic characteristics of patients with hepatic lymphoma diagnosed using image-guided liver biopsy techniques. Leuk Lymphoma. 2011;52(11):2130–4.PubMedGoogle Scholar
  74. 74.
    Fu DA, Campbell-Thompson M. Periodic acid-Schiff staining with diastase. Methods Mol Biol. 2017;1639:145–9.PubMedGoogle Scholar
  75. 75.
    Agmon-Levin N, Berger I, Shtalrid M, Schlanger H, Sthoeger ZM. Primary hepatic lymphoma: a case report and review of the literature. Age Ageing. 2004;33(6):637–40.PubMedGoogle Scholar
  76. 76.
    Anthony PP, Sarsfield P, Clarke T. Primary lymphoma of the liver: clinical and pathological features of 10 patients. J Clin Pathol. 1990;43(12):1007–13.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Swerdlow S, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2017.Google Scholar
  78. 78.
    Salmon JS, Thompson MA, Arildsen RC, Greer JP. Non-Hodgkin’s lymphoma involving the liver: clinical and therapeutic considerations. Clin Lymphoma Myeloma. 2006;6(4):273–80.PubMedGoogle Scholar
  79. 79.
    Zucca E, Gregorini A, Cavalli F. Management of non-Hodgkin lymphomas arising at extranodal sites. Ther Umsch. 2010;67(10):517–25.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of PathologyH. Lee Moffitt Cancer Center and Research InstituteTampaUSA
  2. 2.Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical CenterLos AngelesUSA

Personalised recommendations